Ashland Inc. (ASH) Earnings Call Transcript
July 29, 2026
Earnings Call Speaker Segments
Thanks, Sandy. I appreciate it. Good day to all of you, and I'm glad you could join us for Ashland's earnings conference call and webcast covering the third quarter of fiscal year 26. I'm Sandy Klugman, serving as Ashland's Director of Investor Relations. With me on today's call are Guillermo Novo, our Chairman and CEO; William Whittaker, our CFO; plus the leaders of our business units. Alessandra Faccin, who oversees life sciences and Intermediates; James Minicucci, who leads Personal Care; and Dago Caceres, who heads Specialty Additives. I want to point out that slides will be used throughout today's call, so we hope you'll follow along using the webcast materials posted at ashland.com in the Investor Relations section. Kindly go to Slide 2. Just a reminder, this presentation includes forward looking statements about our fiscal 26 outlook, along with other topics spelled out on Slide 2, and in our Form 10 Q. Such statements carry risks and uncertainties that might make future results differ materially from the projections we share today. We consider these statements to rest on reasonable assumptions, yet we cannot guarantee those expectations will be met. We'll also mention certain adjusted financial metrics. These include both actual and projected figures, which count as non GAAP measures. We offer these adjusted numbers so you gain extra insight into how our ongoing business is performing. GAAP reconciliations can be found on our website and within the appendix of these slides.
I'm going to pass things over now to Guillermo so he can share his opening comments. Thank you, Sandy, and hello to everybody who has joined us. If you would, please navigate to slide 5. All in all, we turned in a robust third quarter, one that showed solid demand, careful commercial execution, and healthy generation of free cash flow. James rose throughout every business unit, and what we achieved matched the expectations we set out when this quarter began. These outcomes demonstrate how well the team executed and strengthen the momentum we're building in each of the businesses. Life Sciences posted double digit sales growth, helped by broad contributions throughout pharma end markets plus continuing momentum from our Globalize and Innovate strategies. Pharma notched volume growth for a 5th quarter in a row, underpinned by strength in high purity excipients, injectables, and momentum from innovation growth. Personal care produced yet another quarter of solid performance. This was led by biofunctionals actives, growth in the high single digits for skincare, and favorable contributions from haircare and microbial protection. Performance showed healthy growth across end markets and major regions, backed by strong customer engagement and adoption of innovation. Specialty Additives achieved encouraging sales growth, consistent with what we expected. Strength in coatings and performance specialties came mainly from market share gains, which shows how well the team executed commercially. By region, most markets were better than the prior year. Intermediates saw higher sales, aided by improving merchant sales that were driven by greater NMP demand in North America EV battery and energy storage applications. On the operational side, our third quarter results showed continuing progress in manufacturing performance, and there's more room to improve. We stay focused on targeted investments and disciplined execution, and we anticipate further progress in the fourth quarter as these actions increasingly pay off. We also produced strong cash flow in the quarter by managing working capital with discipline, and we closed the quarter at a net leverage of 2.4x, which brings us back into our long term target range and strengthens our capacity to invest in growth and innovation. Kindly go to Slide 6. What we delivered showed the strength of our execution and the payoff from the actions we've taken throughout the portfolio. Sales climbed 7% year over year, which reflects broad based growth across the portfolio. Profitability took a hit from production challenges we ran into earlier in the fiscal year. Results got better sequentially and came in largely as we expected. We keep making steady progress throughout the manufacturing network and on our strategic priorities. Our teams stay focused on commercial execution, pricing realization, and cost discipline. Pricing actions keep gaining traction, offsetting higher raw material costs while we maintain strong customer relationships. Please go to slide 7. Slide 7 shows just how broad our growth is and the quality of our earnings profile. First, our consumer focused businesses, Life Sciences and Personal Care, keep producing attractive margins, supported by resilient demand, innovation, and favorable mix. Second, the Innovate and Globalize strategies keep delivering measurable results, with momentum accelerating in higher value applications across the portfolio. During the opening nine months of this year, Innovate has already surpassed what it aimed to achieve for the entire year, while Globalize has now fully met its annual goal as well. On top of that, we keep producing solid outcomes throughout the platforms. Third, although our margins still show the impact of the production rate difficulties we faced earlier along with pressure on costs, the steps we've implemented in pricing, manufacturing, and commercial execution keep building momentum. Because of this, we're in a strong position to see additional gains in profitability during the fourth quarter. Before I hand things over to William, I'd also like to take a brief moment to mention that yesterday we made public a cooperation agreement with Ancora, one of Ashland's shareholders, with whom our discussions have been productive. Through this agreement, we're bringing Peter Thomas and Alan Spizzo onto Ashland's board as independent directors. Each of them carries substantial executive and financial expertise in specialty chemicals, and we're confident their viewpoints will help sustain our ongoing emphasis on generating value for shareholders. In addition, the board is setting up a capital allocation advisory committee to add greater rigor and objectivity to how we plan and strategize around capital allocation. We appreciate the continued engagement we have with our shareholders and are eager to collaborate with Peter, Alan, and the remaining members of the board as we keep carrying out our strategy. Now, let me close with 3 key takeaways before we move into the financials. Across our core businesses, demand stayed healthy. Our innovate and globalize initiatives keep driving meaningful growth, and we continue making headway on the operational challenges we've talked about all year long. These are positive signals for the business and strengthen our confidence in the opportunities that lie ahead. At this point I'd like to pass the call to William so he can give a more detailed look at third-quarter financial performance.
Thanks, William. Let's move to slide 9. Third-quarter sales reached $497 million, up 7% versus the same quarter last year, driven primarily by stronger volumes across all of our business units. Portfolio-wide, volumes climbed 6%, with life sciences and personal care still performing well, while specialty additives returned to growth and intermediates benefited from improved merchant demand. On the pricing side, we rose roughly 1% year over year, led by life sciences and specialty additives, representing about 300 basis points of sequential gain. Foreign exchange contributed roughly $3 million, or 1%, to sales. Adjusted EBITDA was $109 million, compared with $113 million in the third quarter of last year. Gains in life sciences and personal care were more than offset by softer earnings in specialty additives and intermediates. Profitability continued to reflect the impact of lower production rates from earlier in the year, plus incentive compensation normalizing off a low base last year. Those headwinds were partially offset by higher volumes, favorable mix, and pricing actions. Sequentially, profitability improved as operating performance strengthened and commercial initiatives gained traction across the portfolio. We expect another improvement in profitability in the fourth quarter. Adjusted EBITDA margin was 21.9%, versus 24.4% a year ago, reflecting those factors. Adjusted earnings per share, excluding amortization expense, was $1.02 compared to $1.04 in the prior year quarter, and it came in at $1.20, compared with $1.40 in last year's third quarter. Cash generation remained a key strength in the quarter. Ongoing free cash flow was $103 million, versus $108 million a year ago, equating to conversion above 90%. Inventory is down nearly $80 million so far this fiscal year, supporting robust cash generation and positioning us better for improved absorption and fewer inventory-related margin headwinds ahead. We ended the quarter with $936 million in available liquidity and net leverage of 2.4x, back within our long-term target range. We also refinanced our credit agreement during the quarter, extending maturities on favorable terms and enhancing our financial flexibility. The balance sheet remains a competitive advantage, giving us room to support operations, invest in strategic priorities, and maintain disciplined capital allocation. With that, I'll turn the call over to our business unit leaders to discuss segment performance in more detail.
Thanks, William. Alessandra, I’ll pass it over to you for Life Sciences now. Good morning, everyone. Please turn to slide 10, which is the life sciences section. We delivered another strong quarter in life sciences, with revenue of $180 million, up 11% versus the same quarter last year. Those results were driven by higher sales volumes, supported by broad-based momentum in pharma applications. Pharma achieved double digit sales growth and recorded its 5th consecutive quarter of volume gains year over year. Demand remained firm across all regions and product categories, including continued momentum in high purity excipients and injectables. We also benefited in the quarter from the timing of customer orders and supply chain normalization. After adjusting for those items, underlying demand trends remain strong and consistent with our expectations. Pricing contributed positively to the results as commercial actions began to gain traction during the quarter, with the full run rate anticipated to be achieved in the fourth quarter. Foreign exchange contributed about $1 million to sales in the quarter. Injectables again delivered strong performance in the third quarter, with exceptional growth that is aligned with our globalized strategy. This performance reflected accelerating adoption of Ashland’s high purity differentiated excipient portfolio. Strong customer demand, a growing development pipeline, and increasing new product adoption support a favorable outlook. We also announced the groundbreaking for our new tablet coating manufacturing facility in India, which is another important step in our globalized strategy. Following recent investments in Brazil, this expansion further strengthens our regional manufacturing footprint and better enables us to serve customers in some of the fastest growing farmer markets worldwide. On innovation, products we’ve launched recently continue to grow above market, led by low-nitrite oral solid dosage excipients as well as high purity injectable and bioprocessing products. Strong customer adoption confirms Ashland’s strategy of investing in differentiated technologies that address increasingly complex formulation and regulatory requirements. On profitability, adjusted EBITDA increased 11% to $60 million, compared with $54 million in the prior-year quarter. Adjusted EBITDA margin was 33.0%, consistent with the prior year. Higher volumes, favorable pricing, and product mix offset the impact of lower production rates and increased SAR expense. Volume growth remained the primary driver of earnings improvement. At the same time, disciplined commercial execution and favorable mix contributed to the results. Looking ahead, life sciences continues to benefit from resilient pharmaceutical demand and growing traction from our Globalize and Innovate strategies. Along with pricing realization and continued innovation adoption, these trends reinforce our confidence in the long term opportunities ahead. Please go to Slide 11 for Intermediates. Intermediates had a solid quarter, with sales of $37 million, up 12% compared with the same period last year, driven by stronger merchant demand. Merchant sales increased to $26 million from $23 million in the prior-year quarter, supported by higher NMP demand from North American EV battery and energy storage customers. Ahead of a planned fourth-quarter shutdown. Sales to captive BDO customers reached $11 million, a modest increase versus last year, driven by consistent internal needs and transfer pricing tied to the market. Currency movements played almost no role in quarterly sales. Turning to profitability, adjusted EBITDA was $4 million, compared with $7 million during the same period a year ago. That decline versus the prior-year quarter stemmed largely from reduced advantages tied to advanced manufacturing tax credits, even though our core operating results remained largely stable. Improved pricing outcomes and firmer demand in electronics—a major merchant application—allowed us to partially counter that pressure in the quarter. The broader BDO value chain still sits beneath its historical levels, yet we are noticing mild but positive signals of recovery. This applies to NMP demand, primarily in energy storage-related uses. Given the market's swings, we remain cautious regarding our short-term expectations. Even so, our longer-term perspective is unchanged, and we continue to see EV battery and energy storage uses as an appealing growth avenue for the company. Adjusted EBITDA margin was 33%, consistent with the prior year. With that, I'll pass the call to Jim to discuss personal care.
Thanks, Alessandra. Let me walk you through how personal care performed. If you'd go to slide 12, that's where personal care is covered. Once again, personal care posted growth for the quarter, which speaks to widespread strength across end markets along with ongoing momentum in our higher value applications. We came in at $155 million in sales, which is a 5% increase versus the same period last year. That was powered by strong volume gains throughout the portfolio, fresh commercial wins, and a beneficial mix. Biofunctional actives turned in yet another quarter of double digit growth, helped by a customer base that keeps expanding. Adoption of Colipepto keeps speeding up, thanks to its multifunctional advantages and its capacity to immediately boost skin radiance, hydration, elasticity, and deliver visible wrinkle correction. Riding that momentum, Biofunctional actives is beginning to record early commercial wins with Essernonite, our 2026 flagship ingredient. Microbial protection likewise posted solid growth, with double digit volume increases in every region; during the third quarter, we held the inauguration and commissioning of our new microbial protection production facility in Europe. This investment bolsters our regional manufacturing capabilities, enhances supply chain resilience in the region, and marks one more major step in globalizing microbial protection. Over in care ingredients, the portfolio saw solid gains, with positive momentum in both hair and skincare markets. Broadly speaking, skincare grew at a high-single-digit rate, haircare grew at a mid-single-digit rate, and oral and home care grew at a low-single-digit rate. Looking at regions, the Americas and China led the way. Pricing came in better than the previous quarter. As commercial actions kept building traction during the quarter. Even though it was somewhat under the prior year. To be clear about pricing, the price actions we took more than covered cost inflation. In microbial protection specifically, the investments we've made globally have brought down our cost structure, which has allowed us to pick up share. Foreign currency added roughly $1 million to segment sales. Moving to innovation; in the third quarter, we completed our first industrial production run of multifunctional starch. Which is a key milestone on the path to our planned calendar 2026 launch. Personal care keeps making solid headway on our Globalize and Innovate strategies. Backed by robust customer engagement and a focus on innovation. Now for profitability. Adjusted EBITDA rose to $45 million, compared with $41 million in the prior-year quarter, And EBITDA margin widened 110 basis points, reaching 29.0%. This mirrors broad based growth across all business lines. The profitability improvement came from higher sales volume and a favorable product mix; to sum up, personal care achieved both mid-single-digit growth and margin expansion this quarter, which shows disciplined execution, a strong customer focus, and ongoing adoption of differentiated and innovative technologies; with that, I'll hand the call to Dago to go over the results of Specialty Additives.
Thanks, Jim. If you’ll move to slide 13. Specialty additives produced sales growth in the quarter, even as demand stayed uneven across end markets and regions. Sales rose 4% from a year earlier, reaching $136 million, helped by share gains, pricing realization, and strong commercial execution in coatings and performance specialties, which are our most strategic industrial segments. Coatings’ recovery came from higher volumes due to share gains in every region, successful innovation, implementation, and pricing discipline. Performance specialties also grew compared with a year earlier. Backed by favorable demand trends and commercial execution; those gains were partly offset by ongoing weakness in construction and energy and resources. There, market conditions are still challenged and generally consistent with recent trends. Construction volumes keep reflecting both softer end-market demand and the effect of deliberate portfolio management actions to preferentially serve more attractive regulated segments. By region, growth was broad based. With almost every region posting year-over-year improvement. It’s worth noting that the Middle East, Africa, India, and China grew despite difficult market conditions and supply chain disruptions. Pricing actions kept gaining traction during the quarter, and along with favorable product mix supported growth even with a muted demand environment. Foreign exchange added roughly $1 million to sales. Moving to profitability. Adjusted EBITDA was $20 million versus $26 million in the prior-year quarter. While adjusted EBITDA margin was 14.7% versus 19.8% in the prior-year quarter. The results were broadly in line with expectations and reflected lower fixed cost absorption tied to earlier and reduced production rates at our Hopewell facility. Those headwinds were partly offset by favorable pricing and product mix. Operationally, we completed the planned turnaround at our Hopewell facility successfully. And put in place a number of process control, productivity, and operational robustness improvements. While we’re encouraged by the trajectory, we see this as an operational improvement journey. To reach our long term productivity targets. The performance of our broader cellulosics acid base remains solid. And we’re using our unique global manufacturing network to increase supply flexibility, optimize production, and strengthen overall supply reliability; we’re also making solid progress across our balanced innovation portfolio. From regional solutions designed for local customer needs to core innovations that strengthen and expand our existing product lines to transformative technologies such as our novel additives, which keep advancing to our commercialization and represent a significant long term growth opportunity for Ashland. Overall, while end market conditions remain mixed, we’re encouraged by the progress being made across the business. Continued price organization, strong commercial execution, and ongoing operational improvements support our expectation for improved profitability over time. I’d like to recognize the team’s strong execution and cost discipline in what remains a challenging market environment.
That brings us to the point where I hand things over to Guillermo. Appreciate it, Dago. If you could go to slide 15. I'd like to give you a quick status report on our Execute strategy along with the work we're doing to optimize manufacturing. As Dago mentioned a moment ago, we've moved more slowly than we first intended when it comes to optimizing our HEC network. Even so, the quarter played out more or less the way we anticipated, our operating performance got better, and we keep pushing forward on the steps required to boost productivity, reliability, and network performance. Outside of HEC, the manufacturing optimization programs we've launched are still proceeding as planned. We now anticipate that VP&D optimization work will produce somewhere around $12 million in benefits during this fiscal year. On top of that, we wrapped up the last stage of our small plant consolidation effort in the third quarter, which brings roughly $3 million in EBITDA benefit this year and makes our manufacturing footprint even simpler. Taken together, VP&D optimization plus small plant consolidation should generate $15 million in 2025. What matters here is that these savings are structural and will recur at that run rate, not one-time items, and they put us in position to start next year with a leaner cost base that's more competitive. Execute is still a central piece of our strategy. There's more work ahead of us, but the wider set of manufacturing programs is producing results, and our confidence remains strong in the long-term value and profitability gains these efforts can create. If you'd turn to slide 16. Our Globalize and Innovate efforts keep delivering meaningful results and stay a key growth engine across the portfolio. Over the first 9 months of this fiscal year, Globalize has already hit its growth target for the full year, while Innovate has gone past its full year objective. On the innovation side, highlights include ongoing momentum in high purity excipients within life sciences, skin longevity technologies in personal care, and formulated rheology solutions for stone paint within specialty additives. As Alessandra and Jim told you, the investments we've made to broaden capabilities and reinforce our regional presence are producing tangible returns; these efforts are raising our exposure to higher value applications, deepening customer relationships, and enhancing both the quality and the durability of our growth profile. Equally important, the pipeline of opportunities behind both initiatives is still robust. That strengthens our confidence that Globalize and Innovate will keep contributing meaningfully to growth and value creation in the years to come. If you'd please turn to Slide 17.
Moving on to what we expect ahead. That picture is mostly the same as before. We still anticipate expansion throughout the portfolio, continued traction in applications carrying higher value, greater delivery on our pricing initiatives, and robust cash flow, and we look for profitability to take another step higher in the fourth quarter. Although operating results stay under where they have been historically, the hit to profitability ought to be softer than what we saw in the third quarter, since operational trends are getting better and pricing efforts keep building momentum. Given that, we are restating our fiscal 26 guidance for sales and adjusted EBITDA; we still look for sales between $1.835 billion and $1.870 billion along with adjusted EBITDA between $385 million and $400 million. Our adjusted EPS forecast is being changed to growth in the low- to mid single digit range, down from mid to high single digit growth, which mirrors a higher tax rate tied to unfavorable discrete items; for the fiscal year, we still anticipate ongoing free cash flow conversion exceeding 50% of adjusted EBITDA; having said that, I will hand the call back to Guillermo so he can talk about how our technology platforms are generating value throughout the portfolio, and then we will open the line for questions.
Thanks, William. If you could go ahead and open to Slide 18. For us, innovation continues to be a main engine behind creating value over the long haul, and it's a key point of difference throughout our portfolio. What we've achieved under our globalize and innovate strategy speaks directly to how strong our technology platforms are, along with our customer partnerships and our R&D capabilities. We're really enthusiastic about how things are going with our new technology platforms. These new technologies carry compelling value propositions and go after big, scalable growth opportunities; given solid customer engagement and validation, we have a lot of confidence in the profitable growth these platforms can deliver. With more than 52 patents filed, they also offer a strong chance to establish lasting differentiation. We're also broadening the range of products and applications these technology platforms can go after; we're speeding up commercialization of new products. So that investors can get a closer look at these opportunities, we'll be hosting an innovation webinar on September 17. At that event, we'll share further insight into our innovation strategy, how we're progressing on developing and commercializing them, and the opportunities we see for creating long term shareholder value. We believe these technology platforms are a meaningful source of future growth — margin expansion and value creation beyond what we currently plan. If you could turn to Slide 19. As we wrap up today's call, I want to restate what gives us confidence in what lies ahead. First, growth is coming back across the portfolio, as the steps we've taken to optimize the business and raise the quality of our mix keep gaining traction. We posted broad based sales growth in every business unit and region, driven mainly by volume growth, strong customer engagement, and disciplined commercial execution. We expect that momentum to carry into the fourth quarter. Second, we stay focused on disciplined pricing execution. Pricing actions are gaining traction throughout the portfolio, which helps us address cost inflation while keeping customer relationships strong. I'd also like to acknowledge our team's efforts in navigating a dynamic environment. Third, our globalized and innovative strategy is delivering. Globalize and Innovate keep producing meaningful results, and we're seeing greater returns from the investments we've made to expand our capabilities, strengthen our regional footprint, and accelerate growth in higher value applications; this is the kind of high quality growth that strengthens our portfolio over the long term. Fourth, operational performance remains an area we're focused on. We're not yet where we want to be, but we are making progress and stay committed to improving our performance; we continue to see meaningful opportunities to strengthen profitability as these efforts advance. And finally, we're extremely excited about the progress we're making on our new technology platforms. We look forward to sharing more about customer validation in the coming weeks. But we remain encouraged by the progress we're seeing across our innovation pipeline and the opportunities it creates across the portfolio. Ashland operates in end markets that hold up well, has technology positions that lead, enjoys solid ties with customers, and possesses an expanding pipeline of chances to innovate. Better demand patterns, greater pricing realization, technology platforms moving forward, and continuous operational gains—taken together, these things strengthen how we view what lies ahead. I want to express gratitude to our employees for their unwavering dedication, and to our shareholders for the support and engagement they keep giving. Operator, please open the line for q and a.
Yes. Morning, everyone. Appreciate you taking my question. I was hoping to gain a clearer picture of the pricing environment you're observing and what our expectations ought to be as we head into Q4 and potentially the early part of fiscal 27? Should we anticipate a significant step-up from where we are now? Will it differ across segments? Basically, how should we frame this? And also the ability to realize what's necessary to offset costs, raw material inflation, other inflation, and so on.
Thank you, John, for asking. Allow me to start by giving a quick reminder to everyone about what this inflation picture represents for Ashland. As you know, we're no longer tied to petrochemicals. Once the adhesive business was divested, our exposure to petrochemicals and to energy-intensive raw materials that demand lots of energy to produce went down; that's true. We aren't shielded completely; there is some effect we have to address, but, as you know, it's considerably smaller; so don't anticipate the kind of price swings you'd associate with commodity businesses. What we aim for is to offset inflation, preserve margins. We're a specialty company, an additives company. Our emphasis is on value-based pricing driven by products, driven by technology. That's the way we grow. We don't treat these periods as opportunities to widen margins. We simply want to ensure we're maintaining them. So that's essentially the foundation. The team has performed extremely well. We've offset all the inflation. Raw materials as well as freight, plus every pricing action we've put in place. Naturally, there's a lag effect. In the coming quarter, I believe we'll see greater advantages simply from the pace of pricing increases relative to the inflation already observed. But fundamentally we're offsetting everything that has hit us, and that will — you'll observe it coming through next quarter. Beyond that, as you know, we'll monitor how markets develop. Mike, during 2022, I believe our priority was acting quickly so we could either maximize or reduce the effect and maximize the gains for us, and the team has accomplished that. So at this stage we're feeling quite confident. But William, would you like to chime in with anything further?
Yes. A few more particular points. I appreciate that question, John. What stands out for us in this quarter is the shift we made, moving from a 2% decline year over year in Q2 to a 1% gain in Q3. Our expectation is that this will keep going. As Guillermo mentioned, we anticipate sequential improvement in Q4. Once pricing is completely in place. Speaking to how big that might be, my expectation is it would be close in size to the sequential gain we just delivered in Q3. And I believe that, on the whole, when you consider pre pricing actions to run rate as we exit the year, it will match the 3 to 8 that Guillermo referenced on the prior earnings call; it will be approximately, it varies region to region, varies product line to product line, naturally, but for the company as a whole we are tracking at the midpoint.
One more thing, John, I want to bring up from the prepared remarks—Jim said something, and I don't want it to be lost in the translation. On personal care, they actually shifted on pricing to recover raw materials. All of that has gone through. I think the team has accomplished a great deal regarding globalization as we regionalize our operations, our infrastructure, and manufacturing. We're altering our cost structure; that has enabled us to do a lot of things; we're gaining a lot of share. But Jim, would you like to comment just to clarify the lower, quote, lower pricing? Is it truly lower pricing within part of your business? So if you could speak to that.
Okay. Appreciate it, Guillermo, and thank you, John. So John, like William said, we're seeing price move up and improve on a sequential basis. Actions were taken by us; back in March, when the conflict broke out, we worked our way through it. Communication with customers got underway. What we've done is raise prices rather than apply surcharges; as a result, some flow-through arrived during the third quarter, yet the steps needed to offset cost inflation were taken by us. Across most of the portfolio. As we noted, particularly in microbial protection, the facility we just commissioned in Europe is now the final piece in making this business global. Assets now exist in every region so supply can be provided regionally, and our cost structure has genuinely been lowered by that. Share gains have truly been made possible by that; so when you look at the overall price impact, that's somewhat of a mix.
Got it, that makes sense — that context is genuinely helpful. Moving to my follow-up, can you speak to the manufacturing optimization, and Hopewell as well, because I'd imagine it belongs in that same category? From what I hear, you're achieving decent progress there, maybe less than what you'd initially hoped for, though still decent progress. How would you have us think about how you wrap up your fiscal year and the tailwinds going into 2027 from these optimization and cost-out initiatives?
Broadly speaking, I'd break out the piece that came from network optimization. If I look at the headwinds we confronted, they come in 2 separate buckets. The events at Calvert City early on — equipment failure, with weather being the biggest driver — I'd put those to one side. Turning to network optimization as such, some things have worked well, and there are gaps we're addressing now. Overall, it has done very well. Across our BPD network, costs keep declining; we've simplified the asset base. Productivity has improved a great deal. I'd call it early days still; some cost optimization is underway, but the genuine productivity push is still in front of us. So in those areas we keep seeing additional room for gains. Every bit of the small plant consolidation has wrapped up. In essence, we just moved production units into our bigger sites. That allows us to take advantage of our overall cost structure. All of it is now done. On HEC in particular, well, there are 2 stories. A plant was shut down. So, you know, $25 million, $30 million are gone. Those costs have been removed. How the benefit has come through, I believe, boils down to 2 matters. We're getting some of the benefit, but it isn't upside anymore; we've used it to fill our plants in China. You know, while we were executing during this stretch, the Chinese market contracted, so the network has been rebalanced. So these days we export out of China. So the benefit appears in sustained margins and improvement. So for us it wasn't a headwind; when it comes to the remaining items that were supposed to be more favorable, I think the real issue now is timing. We moved production of a different product mix over to Hopewell; it's not as if, you know, you flip a switch and production begins. the process technology is different. You know, we stopped the plant; the production rates we wanted weren't being reached. As Dago mentioned, we ran a turnaround. That turnaround worked. We put in new equipment and process controls, so we can drive that productivity; it has only just started up. it's running well. As for what we're producing, output hasn't reached our target yet, and raising it is precisely where our attention is. Reaping the reward from that takes a quarter or 2 — it isn't just about getting the performance with recap and all the rest. Eventually, it will flow through to the P and L. Even so, that remains our biggest issue. When we look back over the year, Calvert plus weather make up those 200 basis points of margin. All in all, this year should have landed 200 basis points higher when it comes to EBITDA and EBITDA margins, and that number is the goal we were hoping to, well, apply as we head into next year while making sure we're in a strong spot. So $25 million, $30 million are gone. Great. Thanks a lot for that perspective.
Thanks, and good morning. Guillermo, regarding the Q4 guidance, which spans roughly $15 million, at this point is there any tilt toward the midpoint, the upper end, or the range as it currently stands?
I'll offer a thought as well, and then William can address each item. At a high level, looking at revenue and EBITDA, on the revenue side we feel quite positive. To begin with, markets are getting better. The core markets have shown resilience, and that has been true for some time. Our personal care and our Life Sciences, particularly pharma, are performing well. Our Globalize and Innovate is progressing nicely; we are achieving all the pricing above inflation that we were aiming for. So where revenue is concerned, the teams are dialed in, customer relationships are strong, and even amid uncertainty, we are executing well in the field. I am confident. So personally, on the revenue side, I feel very, very good. On the EBITDA side, it really comes down to operating performance. As you know, on the prior call we shared that we were facing issues. From my standpoint, I am going to be more careful about how much we commit to regarding the pace of improvement, 1, because that improvement has to be driven over time and, 2, the flow through, as we have discussed previously, is not simple. So we want to be somewhat more cautious there. But William, would you like to add anything?
Yes, I do. We made a deliberate decision not to move those figures up to the middle of the EBITDA guidance range. Let me walk you through a few of the elements that give us confidence here. First off, to land at the EBITDA midpoint, we'll need a stronger outcome on the sales range. As it happens, that's exactly where our internal modeling sits at present, so there are a number of reasons we've remained constructive. For starters, June was a solid finish. Then July and August order builder looked encouraging. As the team mentioned, Q3 was driven by volume, and my expectation is that Q4 will deliver more of a balance between volume and some of the pricing actions we just discussed. If you look at it segment by segment, for life sciences, my expectation is that both revenue and profit stay level from one quarter to the next, which, incidentally, would make for yet another strong and dependable quarter. On the Personal Care side, momentum remains widespread — we're seeing it in the mix of what we sell and in rising margins. Broadly speaking, and you picked this up from what we said earlier, our stance on additives has shifted toward cautious optimism, though the team's commercial execution gives us reason for encouragement. To build on what Guillermo mentioned, the same cautious optimism applies to manufacturing. That area is a major priority for us, and there's genuine room to do better. We also anticipate steady gains as we move through Q4. What's behind that expansion in margin for the fourth quarter? First, we're seeing prices come through. Second, sales volume keeps building with a favorable mix, Globalize and Innovate remains a standout performer for us so far this year, and lastly, operations are getting better step by step.
That's quite useful.
Guillermo, regarding Globalize and Innovate, once more, congratulations on how well things have gone so far this year. Do you have any initial ideas about targets for 2027 tied to Globalize and Innovate?
Yes. I believe we'll be providing an update. As we've done before, we've aimed to be open about the headway being made. On Globalize specifically, plenty of investments have gone in. Only a handful have actually started producing results so far. So we intend to keep shining a light on how we're performing, not only for your benefit but internally too, since it adds much more pressure and greater visibility around our goals; that's proceeding nicely; when it comes to innovation, an update will come in September. The main challenge we're confronting right now across each business — Dago touched on this during his remarks — is that we're seeing far more momentum, not only with the new technology platforms but within the businesses themselves. As you know, when innovation becomes the focus, it transforms everyone, everyone's priorities. There's considerably more effort going into even core innovation, developing new offerings involving new cellulosics and similar materials, adapting them across the various businesses. So much more is happening. We'll likely broaden things as time goes on, though perhaps not by September. What we're working on isn't solely new technology platforms. It's about identifying which scalable innovations truly present a chance to generate growth, to generate margin expansion, and above all, to generate differentiation. I believe this is 1 of the difficulties our industry faces — you know, intense competition, commoditization, that sort of thing. Pursuing that is going to be an essential focus. So in September, we'll share with you, we'd like to offer a bit more detail regarding which key technologies are more scalable, which markets we're going after and sizing those markets, the potential, Naturally, the commitments will come as a range. So we want to demonstrate the path we're on, but all of these are going to be scalable. And once more, what thrills me is that it's a portfolio. It isn't 1 project where everything is riding on it. It's a set of exciting projects with substantial growth potential for a company of our size. Thank you.
This is Christopher here. Let's move to the life sciences segment. I'd like to dig into how durable that pharma volume increase really is. It looks like momentum has built over the past 2 quarters. You've put money into both OSD and injectables. Is there anything coming that would give you a stronger level of conviction, particularly when it comes to OSD? Anything involving GLP-1s? Any new offerings? I realize there may be some smaller periods in there, but the trajectory appears favorable. Thank you.
Bruce, I appreciate the question. Let me give a brief remark and then I'll turn it to Alessandra to see if she wants to add; but no, the momentum within life science and pharma in particular, it isn't, you know, innovation alone, but Execute has played a very significant role. You know, addressing our cost structure, boosting how competitive we are. Within our core businesses that's a major focus area. So that's what gives us confidence that, you know, it's the base business. If demand expands or holds steady, we're going to perform well. Of course, beyond that, there's plenty of new innovation the team is working on. But Alessandra, would you like to say a few words?
Yes, absolutely. So Chris, generally speaking, regarding our goal of mid single digit expansion in life science, that's our expectation for 2026. That's the way to view it quarter by quarter. As Guillermo pointed out, concerning oral solid dose, BDP has been leveling off, which is encouraging. We're also seeing strong traction from our globalizing innovation strategies — injectables, bioresorbable polymers, sugars, and cellulosics are all performing well. Beyond that, we're enthusiastic about launches in additional segments, including the TVO in crop care, where customer uptake is happening and responses have been favorable. No revenue contribution yet in 2026, but it demonstrates the forward momentum. On your particular question regarding GLP-1 — Ashland is gaining and will gain substantially from the expansion of GLP-1 medications that we're witnessing and anticipate seeing sustained upside from going forward, via both the chemicals utilized in API production and the excipients employed in oral solid. In the weeks ahead, you'll see us introduce a permeation enhancer, and prelaunch interest is building; that launch will take place during the month of August. But on the whole, we see momentum from globalize, Innovate, and naturally, within a market that's stable.
Alessandra, could you say a few words about permeation enhancers? For those on the call who might not know this area well, what exactly are they?
Right. So essentially, when it comes to biologics, this aids in getting them absorbed when taken by mouth. That's the thing we're bringing out in August, then, as I said, we've got solid momentum, with pre launch sales already happening.
Understood, and as a fast follow-up, a comparable inquiry regarding personal care. Clearly, the portfolio has experienced quite a bit. A great deal of changes, restructurings, and outages have occurred, and those clearly were spread out at intervals across a few of the segments; it appears you are also generating solid momentum here, particularly in skin and hair. I was somewhat interested regarding your perspective on that, how much of it is simply, you know, an absence of destocking? Certain customers of yours have undergone their own restructurings. In certain instances, multiple restructurings. Regarding your outlook and your level of confidence in that portfolio, you know, where do you sit compared with the last, you know, 6, 12, 18 months? Is this, you know, maintainable in fiscal 27? And, you know, if it is, what is driving that the most? Thank you.
Hey, Christopher. Appreciate the call; so I believe if you zoom out and examine the year, right, I mean, during Q1, we had pointed out that certain customer specific outages took place primarily in North America. Once you adjust for those in Q1; we had low single digit growth. During Q2, mid single digit growth. This quarter, once again, mid single digit growth. Everything driven mostly, yet exclusively, by volume; and then when we look toward the following quarter, we anticipate being within the same ZIP code mid single digit growth. So, for the entire year, we anticipate finishing mid single digit compared with prior year. And I believe we have established that momentum, right? If you examine biofunctional actives, during Q3, we achieved nearly 30% growth in biofunctional actives. We have been extremely bullish regarding the technology; we possess a great technology. What do we need to do? We need to build the team. We need to build the pipeline. Engage with customers, and then convert that pipeline. And that is precisely what is occurring. And that model is moving through every one of the business lines. Great technology. We built the team; we engaged with customers; we built the pipeline; and now we are beginning to see the advantage of that; and there is that lead time building the pipeline, which we did last year. And then this year is truly, truly converting on that pipeline, and it is coming through in the volume growth; and I believe the genuinely thrilling part is that it is broad based. I mean, if you examine biofunctional actives, 30% growth in the quarter. We are both on trends with exosomes PDRN but then we are setting trends. And developing a new ingredient in Biofunctional actives. We will share a bit more. We are still filing the IP on that. But this is genuinely going to be the next blockbuster hit in this segment. Microbial protection double digit growth on a volume basis across all regions. The money we've committed has already been deployed to take that operation worldwide and to spread our manufacturing base across regions. Market share is moving in our favor, and when it comes to care ingredients, things are going quite strongly for our guars, our cellulosics, and our BPD. That makes it genuinely wide-ranging, and we anticipate keeping this momentum going as we move into the following year. Thanks so much.
Thanks. From what I understand, the activists were pushing for Ashland to conduct a formal sales process. Did we reach any agreement to actually go through with a formal sales process, or does that decision still rest with the new board committee that includes the 2 new directors?
John, I appreciate you raising that. Clearly, that's the topic hanging over everything that everyone keeps bringing up. Here's where we stand. Above all else, our team remains focused on executing our strategy. One point that comes through clearly across all the communications — our own, even the letter from Ancora, and from what we've heard in conversations with many other investors — is that this portfolio holds tremendous value; we've got strong fundamentals that will fuel value creation going forward. And honestly, that ranks as our top priority. Everyone is aligned on executing and driving performance, and that's exactly what will generate the greatest value and the widest set of alternatives. As for our strategy — and let me be direct about our board — we already have a solid board in place. We've been evolving the board over many years now; we've brought in experts covering every business segment we operate in. Our strategy gets reviewed by the board on a regular basis. It's not as though we just woke up recently because an activist or some investor showed up. We've been doing substantial work for a long time, and I've had these conversations with all of you. Regarding how we see the market, the industry, the shifts underway and taking place, and the possibilities that might emerge in the years ahead — none of that has shifted. What has shifted, I'd say, is that we engaged with Ancora. We actually had a highly constructive conversation. They approached things constructively; so did we. I believe everyone grasps the businesses and the issues involved. They put forward 2 very strong directors. Those individuals can bring value to our business. Their experience is relevant to what we're doing; so we viewed it as an excellent chance to strengthen the board. Fresh perspectives will feed into our strategy work. The committee will now be bolstered with additional new viewpoints; and I'll tell you this — we're going to let them carry out the work they've been doing and keep doing. We won't speculate about what they may or may not want to pursue. In my view, making recommendations to the full board about what that process should look like falls to them. But the top priority we're all aligned on is execute, drive performance, and generate optionality around value, whether organic or inorganic. We want to ensure we hold every option. This isn't a situation where you'd want to be forced into 1 path. We want to make certain we have ways to create value in multiple directions alongside our shareholders.
Alright. Then for my second item, I just want to clarify something. When the intermediate segment came up, this was the first time I can recall hearing anything regarding those tax credits tied to advanced manufacturing. As far as I can tell, NMP on its own wouldn't be eligible, right? So what you're picking up is really a knock-on benefit coming from the battery buyers further down the chain?
William, do you want to — yeah. No, John. Actually, we brought this up around this same point last year. So to jog your memory, there's an incentive tied to producing domestically within certain critical industries, and battery is one of them; our cost standing does get better because of it. It makes companies producing here more able to compete. The idea behind it first came up a couple years back, though the qualifying criteria got spelled out more clearly during Q3 of last year. So when you compare one year to the next, the Intermediates business faces roughly a $3 million headwind, yet on a sequential basis it's holding steady. We'd anticipate keeping this and remaining eligible for it until at least 2029, after which it keeps winding down gradually. Great. Thank you.
Morning, everyone. I'd like to build on one of the questions John raised earlier regarding cost savings and how those carry into 2027. Your response was fairly straightforward — you indicated this year's margin could improve by 200 basis points, which works out to roughly $40 million in EBITDA. What you said about Hopewell sounds somewhat more positive this quarter compared with the prior couple of quarters. So would you now anticipate a larger portion of that $40 million landing in 2027, or does it remain roughly a 2 year timeline? Previously, I believe more of the benefit was expected in 2028.
We should begin to observe that carry-through — let's frame it by quarters. It ought to begin around the second quarter, meaning starting with Q2. In Q4 and even Q1, given how recap functions, there will be some noise, which is exactly why we're taking a more careful stance; it isn't only about our actions, but also how those actions move through the P and L at present. Beyond that point, though, we ought to begin seeing that carry-through. Certain pieces, such as the Calvert downtime, will show up sooner since we're already running there. So of that $40 million, some portions need more time while others will arrive, and you'll begin to notice some of those gains. What we're most focused on at the moment is getting productivity right at Hopewell — specifically kilos per hour output for a particular segment of our product line — ensuring we achieve the proper throughput and the proper cost structure as we go forward. All right. Thank you.
And if I might add one brief follow-up regarding specialty additives. What I mean is, it appears you feel more at ease, or at minimum more assured, about volumes in that area. We have heard talk of new wins for some time now, yet it feels as though they have not materialized. And architectural coatings demand, I mean, is not all that robust. So what is driving the confidence at this point that we will witness better volumes across the coming couple of quarters, or perhaps a year?
So a fast remark. Dago, perhaps you could weigh in. The positive side here is the benchmark, you know, given what took place in 2024, the markets have settled down. I mean, they are not sitting at the peak, I would say, but at minimum they are steady. We are beginning to observe share gains, and Doug will speak to that. So many moves are now in place that let us start regaining that momentum. But Dago, why do not you go area by area and simply provide us with something like a picture of what is going on?
Alright, then. Let me take it market by market, since architectural coatings really do differ a lot from one region to another. In China, what you're seeing is still fairly steady. I'd say, actually, that on the new construction side it's shrinking; that said, in other industrial uses, electronics for instance, we're performing quite strongly. The real key in China, though, is how well the team executes. We've managed to turn the innovation we're doing locally into actual dollars; that's really coming from the team. Europe — Europe is flat. No recovery signals at all. Germany and France are the drivers behind that. Still, in that region too, we've stayed very disciplined, particularly on share of market and on execution. The other major region for us, obviously, is North America, and North America is still the million dollar question. New construction remains quite sluggish. Yet we're aware there's pent up demand; so interest rates will decide it. So first and foremost, it comes down to consumer sentiment to tell us when that inflection point arrives; the encouraging part across every region, though, is that innovation keeps moving forward. That accounts for a large share of the growth we're currently seeing. Commercial discipline is strong; we're therefore extremely cautious about how we set prices. We are purchasing — pricing our products. And then pipeline execution, which matters enormously if we're going to beat the market; so that's broadly where things stand. The markets, I'd say, are stable. On architectural coatings, there's genuinely nothing to report. Performance specialty is exceeding expectations. Thank you.
Thank you so much. From what I can tell, you've aimed to improve your cash flows during this year by lowering your operating rates. What kind of hit did that put on your EBITDA up to now in this year, or across the whole year?
Hello, Jeffrey. Good morning. That's a solid question. In fact, it ties into the remark Guillermo made regarding those 200 basis points. So I'd tie roughly $80 million of inventory drawdown to that, and if you ask how much of it involves absorption, affecting EBITDA, it's likely 30 million to 35 million. And so, truly, when we think about heading into the next year, that's the most obvious path we have toward a margin recovery. It means producing to demand; and I mean, it connects to the way Guillermo framed it, though it's quite similar; so you're correct. It did strengthen the balance sheet, a significant inventory drawdown; at the Ashland level, we don't anticipate significant inventory swings moving ahead. Naturally, you know, specifics count. So depending on product line, certain areas might get rebuilt while others could hold inventory beyond target. But broadly speaking, the major inventory swings are what has occurred so far this year. And starting now, I'd anticipate stability. And, Jeffrey, I mean, this is one area of discipline we're genuinely transforming, and you know the past and simply how inventory was handled; we don't want to push performance by accumulating inventory. So we'll be far more disciplined about building as demand rises. I do believe there's upside potential for us since we have we have lowered it. But we are we are simply not going to begin producing just artificially to generate absorption. We are we are going to balance our actions based on informed views of demand.
Earlier during this call, did you mention that a reversal occurred in the intermediates and solvents segment during Q4? And should one exist, does it matter significantly to you? When looking at EBITDA?
What we reversed happened at Hopewell; we had halted operations there for a stretch since we'd put money into it. Machinery, to address certain processing problems we'd been encountering; thus the facility is operating again and generating output, and right now we're tracking output levels as they increase.
And so, finally, regarding the capital allocation committee that's been set up, when do you think that committee will come forward with a recommendation, or does that committee have no timeline at all?
Well, I won't guess about that, but 2 new directors have just been appointed. We need to get them onboarded. There's a great deal of work we have to do in order to get them fully informed; the board has been focused on our strategy for quite a while now. So we won't be halting at this moment; the task is really to get them fully informed and let them carry out their work; but I won't guess about how quickly that happens or anything like that — that's for them to decide; and what their opinions will be, what they'll suggest to the board. Okay. Great. Thank you.
Hello. I'm curious about the kind of feedback you're getting from customers on the different innovation platforms — and I'm not talking about near-term technology fads. What I really want to know is what they're saying about the scale of the possible applications, and what you'd need to deliver before there could be discussions about something more ambitious — you know, where they'd be willing to fund capacity or form JVs in certain areas where that makes sense. Or is the whole strategy just Ashland going it alone?
I think that's a great question. I don't want to give away what we've got lined up for our September 17 event. So if anyone wants the full answer, they should join us there. That said, you know, we're feeling a lot of excitement. Personally, I'm much more confident. I've been on the road and visiting our largest customers around the world, and we're meeting with — we're getting in front of many more people: technology people, marketing people. The whole character of the interaction has changed. Because at this point — I believe we've proven the technology. Now the question is: can we find the right product or the right formulation that they want to launch? And can we slot into their reformulation plans when they take on their big brands, whether that's personal care, whether that's coatings? Or even some of the life science ones. So the feedback has been very positive. I can tell you, hey. The silicone replacement in personal care is looking really exciting. Then growing the novel, the modified multifunctional starch — extremely exciting. The work we're — we're getting feedback that's very strong and then some. We had been focused on carbon replacement. So microplastic acrylic based thickeners and all that; but now the sartorial. there are lots of other benefits there that people are excited about. So skin, it isn't just for her hair, but now in skin too. We've got both of those markets really doing well. The super wetter is now moving into a great many different markets. You know, 1 area where we hadn't expected to move that fast was in personal care, and actually we've now found a home when it comes to ethnic care. For applications that can wet and condition hair much more quickly. I think as Alessandra said about the TVO for ag, We've got it in the seed coatings; they're now working in the oil dispersants. that too is very, very exciting. The super wetter is doing well in that space. I'm personally — and I'm biased. I'm genuinely excited by what coatings is doing. That really fits better with my prior history. The — the TiO 2 spacer technology we're working on has been very well received by customers; we haven't sampled that 1 yet since we were securing all the IP. That work is underway, and I have to say, it is incredibly exciting. Regarding those specific instances I mentioned—what we're looking at here is a massive addressable market, and that's really the focus of the meeting. The silicones that go into personal care, that's an $800 million market. There's a lot of headroom there. We're not talking about $34 million here; we're going after some big opportunities. Think about rheology—acrylic-type chemistry, synthetic chemistries—the ability to replace that is huge. By that I mean, that represents $4.5 billion in business that we're going after. TiO2 replacement: if we can get to 10% to 20% TiO2 efficiency, you can do the math on how much TiO2 gets used in different types of paints and architectural applications. And agriculture is also a very, very big market—so scale is really the name of the game. And what I'd add that gets me excited is this: externally, we've talked about the new technology platforms; going forward, you'll hear us talk about technology platforms, because there are a lot of other spaces we're now moving into with our existing technology, and we see opportunities to go after scalable ones too, especially in cellulosics, which I think will change things over the next couple of years. It's probably $30 million to $35 million. How do we move toward new things that we can bring to the technology? There hasn't been a lot of innovation in that space in a long time, and that's what really has me enthusiastic. Thank you.
Morning, everyone, and thanks for taking my question. A lot has already been covered, so perhaps just a quick one on life sciences. I believe somewhere in the materials, there was talk about customer order timing that benefited the quarter. Just to clarify, did that capture something pushed out of the second quarter, or was it pulling something forward from Q4?
Oh, sorry. Do you want to comment? Yeah. So to some extent from the second quarter, but as I mentioned, if you are looking across second, third, fourth quarter, we target mid single digit growth, and that is what we expect looking across the year and across those quarters; that is and we are talking about the fundamentals, right, the market is stable; we are seeing great momentum with GlobalEye. Innovate, with the growth on injectables, cellulosics portfolios. Definitely, it is the underlying fundamentals are there.
And it the order pattern was not was not no material.
Alright. Thanks. I appreciate that.
Hello. Thank you for taking my question. I was just hoping you might elaborate a bit more on the underlying demand you're observing — the end demand fundamentals — within the nutrition business, and what specifically drove that decrease for you.
Regarding nutrition, we're discussing the projects we have and collaborating with customers on new applications, with an emphasis on enhancing our mix as well. Leaning toward a better mix. And new wins are arriving, but they're arriving below our expectations; so we observe that the momentum behind these new applications is simply arriving more slowly than we had expected. And essentially, as we've discussed nutrition previously, right, the — you know, the applications outside of meat. This is a market that hasn't taken shape, correct? The growth still isn't present. So we're definitely concentrating on other applications within our nutrition portfolio; we're noticing that. The wins are simply arriving below our expectations; however, in the third quarter specifically, looking just at nutrition, revenue held steady. There was no decline. Alright. Thank you.
Hello, and good morning. I have just one question. In the part of your strategy that involves globalization, it seems like you are gaining solid momentum from the present set of investments, which I believe were made roughly 2 years back. So I want to ask: do you still believe certain gaps or areas exist that will require additional investment, and how might the schedule for another wave of globalized investments look? Thank you.
I believe most of the major investments are already behind us. Taking it by business: in microbial protection, as Jim noted, we currently have local supply across every region — Brazil, North America, Europe, and Asia. That makes a difference. It is not merely the fact that we are back integrated; we also achieved an improved cost structure on several key actives moving forward. This gives us a far stronger competitive standing and lets us formulate locally with locally sourced raw materials, so the advantages are substantial. For biofunctionals, we have capabilities now in Europe, and we intend to build those up further — you know, in Brazil we have capabilities. And in China — I think in the US, that is 1 where we want to bring production here as well, so we can operate closer to our customers. Those are not major investments, but we will add that capability at the appropriate moment. In tablet coatings, as Alessandra said during her remarks, India represents a large market for us. So we ought to have the new plant — they performed the groundbreaking — and by the middle of next year, we should be producing. Customers are quite enthusiastic about, you know, some of the products we have been launching, but you have to be local to truly compete in that area. And I would say that on the injectable side, we have already completed most of the investments. I think, you know, in Ireland, the investment we made was larger than needed, so we can keep building samples, but we are already achieving our first commercial sales, and that began to ramp up, so we are well positioned there. And for high purity excipients for injectables, sugars, and other products — cyclodextra — we made the investment here in the US in Columbus, Ohio, and we are ramping up production there. So we are in a good place. I mean, that is something that, as we grow, we could place in another region later on, but that would be further out. So I would say biofunctionals and tablet coatings would be the areas where I could see some investments. Hopefully, I think the issue will be with new technologies coming in. My guess is that's the one where we'll likely direct investment toward taking those product lines worldwide as they go commercial. All right. Thanks.
Thanks to each of you for joining and for your questions. We’re eager to be in touch with all of you across the next few weeks, and above all, I’m looking forward to bringing you an update on September 17 during the webinar focused on innovation, covering how far we’ve come with those new technologies. So I hope to see you soon. Thank you.
We appreciate everyone joining us on this call today. That brings the program to a close. You are free to hang up at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Ashland Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Ashland Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.